Share on StockTwits

Agios Pharmaceuticals (NASDAQ:AGIO) Director John Maraganore bought 2,300 shares of Agios Pharmaceuticals stock in a transaction dated Monday, June 23rd. The stock was purchased at an average cost of $43.98 per share, for a total transaction of $101,154.00. Following the completion of the acquisition, the director now directly owns 48,883 shares of the company’s stock, valued at approximately $2,149,874. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Agios Pharmaceuticals (NASDAQ:AGIO) traded up 0.05% during mid-day trading on Tuesday, hitting $44.04. 225,668 shares of the company’s stock traded hands. Agios Pharmaceuticals has a 52 week low of $15.77 and a 52 week high of $50.37. The stock’s 50-day moving average is $39.35 and its 200-day moving average is $34.96. The company’s market cap is $1.495 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.38) by $0.01. On average, analysts predict that Agios Pharmaceuticals will post $-1.47 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on AGIO shares. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 16th. They now have a $60.00 price target on the stock, up previously from $55.00. Separately, analysts at Zacks upgraded shares of Agios Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 6th. They now have a $44.80 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Agios Pharmaceuticals from $51.00 to $65.00 in a research note on Monday, April 7th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. Agios Pharmaceuticals presently has an average rating of “Buy” and an average price target of $51.70.

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (NASDAQ:AGIO) are treated.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.